CRSP

48.75

0.25% -0.12

Dopo l'orario di chiusura: 48.50 -0.25 -0.51%

Crispr Therapeutics Ag (CRSP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CRSP Giù? Forum Previsione

Precedente Chiudi:

$48.87

Aprire:

$49.7

Volume 24 ore:

1.97M

Relative Volume:

1.05

Capitalizzazione di mercato:

$4.68B

Reddito:

$3.51M

Utile/perdita netta:

$-581.60M

Rapporto P/E:

-7.4833

EPS:

-6.5145

Flusso di cassa netto:

$-345.93M

1 W Prestazione:

-13.72%

1M Prestazione:

-8.14%

6M Prestazione:

-13.35%

1 anno Prestazione:

+16.10%

Intervallo 1D:

$47.53

$50.07

Intervallo di 1 settimana:

$47.53

$59.06

Portata 52W:

$30.04

$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Nome

Crispr Therapeutics Ag

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(617) 315-4600

Indirizzo

BAARERSTRASSE 14, ZUG

Dipendente

393

Cinguettio

@crisprtx

Prossima data di guadagno

2025-10-31

Ultimi documenti SEC

CRSP's Discussions on Twitter

Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRSP Crispr Therapeutics Ag	48.75	4.68B	3.51M	-581.60M	-345.93M	-6.5145
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-09-18	Iniziato	JP Morgan	Overweight
2025-02-14	Aggiornamento	Evercore ISI	In-line → Outperform
2025-02-12	Aggiornamento	TD Cowen	Sell → Hold
2025-02-03	Iniziato	H.C. Wainwright	Buy
2024-08-06	Reiterato	Needham	Buy
2024-08-02	Iniziato	Rodman & Renshaw	Buy
2024-06-28	Ripresa	Guggenheim	Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-12-11	Downgrade	TD Cowen	Market Perform → Underperform
2023-10-17	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-09-27	Iniziato	Mizuho	Buy
2023-08-17	Aggiornamento	Citigroup	Neutral → Buy
2023-05-30	Iniziato	William Blair	Outperform
2023-04-13	Iniziato	Cantor Fitzgerald	Overweight
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-03-17	Iniziato	Bryan Garnier	Buy
2023-03-07	Iniziato	Robert W. Baird	Neutral
2022-10-11	Iniziato	Morgan Stanley	Underweight
2022-08-09	Downgrade	Barclays	Overweight → Equal Weight
2022-06-23	Downgrade	Evercore ISI	Outperform → In-line
2022-06-17	Iniziato	BMO Capital Markets	Outperform
2022-04-28	Iniziato	Credit Suisse	Neutral
2021-12-07	Iniziato	Cowen	Market Perform
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-06-14	Aggiornamento	Citigroup	Sell → Neutral
2021-04-21	Aggiornamento	Jefferies	Hold → Buy
2021-03-04	Iniziato	JMP Securities	Mkt Outperform
2020-12-10	Reiterato	Chardan Capital Markets	Buy
2020-12-10	Downgrade	Jefferies	Buy → Hold
2020-12-10	Reiterato	Needham	Buy
2020-12-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-10-23	Iniziato	RBC Capital Mkts	Sector Perform
2020-10-05	Iniziato	BofA Securities	Buy
2020-07-28	Reiterato	Needham	Buy
2020-07-14	Iniziato	SunTrust	Buy
2020-06-15	Reiterato	Canaccord Genuity	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-03	Downgrade	Evercore ISI	Outperform → In-line
2019-11-19	Aggiornamento	William Blair	Mkt Perform → Outperform
2019-11-12	Aggiornamento	Oppenheimer	Perform → Outperform
2019-08-01	Iniziato	Jefferies	Buy
2019-07-26	Iniziato	Canaccord Genuity	Buy
2019-06-10	Iniziato	ROTH Capital	Buy
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-14	Iniziato	William Blair	Mkt Perform
2019-01-28	Downgrade	Goldman	Buy → Neutral
2019-01-22	Downgrade	Citigroup	Neutral → Sell

Mostra tutto

Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie

Mar 13, 2026

Cathie Wood’s ARK Invest Buys $10M in CRISPR and PayPay on Thursday - MEXC

Mar 13, 2026

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - Yahoo Finance

Mar 13, 2026

Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst - MarketBeat

Mar 13, 2026

Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering - Sahm

Mar 13, 2026

Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? - MSN

Mar 13, 2026

Mar 12, 2026

ARK Investment Acquires 113K Shares of Crispr Therapeutics (CRSP) - GuruFocus

Mar 12, 2026

Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 2,800 Shares of Stock - MarketBeat

Mar 12, 2026

CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 9,798 Shares - MarketBeat

Mar 12, 2026

CRISPR Therapeutics (CRSP) counsel sells 2,800 shares to cover RSU taxes - Stock Titan

Mar 12, 2026

CRISPR Therapeutics (CRSP) CEO RSU vesting and 9,798-share tax sale - Stock Titan

Mar 12, 2026

CRISPR Therapeutics plans $350M convertible notes offering By Investing.com - Investing.com Nigeria

Mar 12, 2026

Research Analysts Set Expectations for CRSP FY2028 Earnings - MarketBeat

Mar 12, 2026

CRISPR Therapeutics prices $550M convertible notes offering By Investing.com - Investing.com Canada

Mar 12, 2026

Mar 11, 2026